US Space Force and NASA Looking to Privatize Nuclear Spacecraft Production

US Nuclear Corp. Announces Third Quarter 2020 Results

Los Angeles, CA. December 1, 2020 – US Nuclear Corp. (OTC: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the third quarter ended September 30, 2020.

• Sales for the three months ended September 30, 2020, were $484,318 compared to $659,325 for the same period in 2019
• Decrease in sales due to the impact of COVID-19 on the company and customers
• Employee work hours reduced by half to help mitigate COVID-19 exposure and transmission, in addition to 14-day quarantine periods for employees who may have been exposed
• Selling, general, and administrative expense were $1,021,507 compared to $1,729,246 for the same period in 2019, the decrease of $707,739 or 40.9% was due to careful money management and lower stock-based compensation
• Stock-based compensation was $542,560 for the three months ended September 30, 2020, compared to $1,150,321 during the same period in 2019
• Net loss of $850,386 due to impact of COVID-19
• $309,632 in accounts receivable, $484,012 in cash, and $1,132,000 in backlogged orders

Robert Goldstein, CEO of US Nuclear Corp., commented:

“Despite many challenges imposed by COVID-19, we managed to have a safe and productive third quarter.  The temporary closure of one of our operating divisions reduced and staggered worker hours, and 14-day self-quarantine periods have fortunately proved successful in ensuring all our workers are safe and COVID-19 free, and while these factors have led to a temporary slowdown in sales and production, the safety of our employees and their families is our highest priority.
(more…)

US Nuclear and Grapheton Brain Implants to Help Immobilized Patients

Los Angeles, CA.  November 2, 2020 – US Nuclear (OTC: UCLE) and Grapheton’s implantable bioelectronic sensors can be used to help treat millions of people worldwide suffering from mobility problems.  Neuroscientists stress there is a large unmet demand to develop implantable sensors and the artificial intelligence required to translate the brain signals into specific commands or actions. As many as 500,000 people worldwide suffer spinal cord injuries every year and approximately 1.7% of the U.S. population or 5.4 million people suffer from some form of paralysis. Furthermore, COVID-19 has caused an increase in the number of strokes, especially among younger individuals.
(more…)

US Nuclear Secures Its Position at Bioelectronics Startup Grapheton

Los Angeles, CA.  October 19, 2020 – In addition to US Nuclear’s (OTC: UCLE) 40% stake in Grapheton, CEO Robert Goldstein has recently taken a seat on Grapheton’s board of directors and will now serve as Chief Strategy Officer. As Chief Strategy Officer for Grapheton, Robert Goldstein will help the business become a leader in the new field of bioelectronics and will cement the partnership between US Nuclear and Grapheton.

Grapheton’s unique, patented bioelectronic implants lead the world in bio-compatibility and longevity. Bioelectronics is becoming popular among researchers and doctors, and the bioelectronics market is likely to experience tremendous growth in the near future. In recent years, there have been numerous breakthroughs using bioelectronics technology. A notable example, bioelectronic devices have been researched and used in clinical trials to treat rheumatoid arthritis and Crohn’s disease by electrically stimulating the vagus nerve to control inflammation and the immune response.

Bioelectronics has the potential to become a vital branch of medical treatment. Medical care, in general, has made many advances in recent years, but there are a great many diseases, conditions, injuries, and remaining unmet patient needs that still need to be urgently addressed.
(more…)

Tritium Monitor Market Soars Due to Construction of $20+ Billion ITER Fusion Energy Project

Los Angeles, CA.  October 6, 2020 – As the construction of the huge ITER tokamak grows towards completion, the tritium monitoring market is soaring. As the world leader in quality tritium monitoring instrumentation, US Nuclear’s (OTC: UCLE) Overhoff division is poised to capture a large portion of this business.

The ITER fusion project seeks to develop a major new source of electric power to help supply the world’s fast-growing appetite for dependable, 24/7 electric power. Fusion is fueled by tritium and deuterium, which are both isotopes of hydrogen.  Tritium is in short supply and ITER will fully deplete the global inventory. ITER is a $20+ billion international scientific and engineering project jointly funded by the European Union, China, India, Japan, Russia, South Korea, and the United States.

(more…)

US Nuclear Corp. Announces Second Quarter 2020 Results

Los Angeles, CA. September 24, 2020 – US Nuclear Corp. (OTC: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the second quarter ended June 30, 2020.

• • Sales for the three months ended June 30, 2020, were $302,201 compared to $1,530,523 for the same period in 2019
  • Decrease in sales due to the impact of COVID-19 on the company and customers
  • Overhoff operating branch was temporarily closed 3 months to allow employees to safely isolate themselves at home
  • Employee work hours reduced by half to help mitigate COVID-19 exposure and transmission
  • Selling, general, and administrative expense were $346,203 compared to $1,246,309 for the same period in 2019, the decrease of $900,106 or 72.2% was due to careful money management and lower stock-based compensation
  • Net loss of $145,117 due to impact of COVID-19
  • $841,000 available cash in the bank with approximately $850,000 of backlogged orders

(more…)

Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage

Los Angeles, CA.  August 3, 2020 – US Nuclear Corp. (OTC: UCLE) aims to combat COVID-19 and help patients and survivors of the virus by working together with MIFTEC to produce an unlimited supply of domestic, low-cost medical isotopes.

The IAEA is supporting more than 121 countries with RT-PCR equipment, which is used to rapidly detect COVID-19 in real-time by a nuclear-derived technique and is one of the most widely used and accurate lab methods. The isotope Co-60 is also being used to sterilize medical equipment, devices, and supplies for COVID-19 professionals to ensure they are safe for use.  Co-60 irradiation is one of the quickest and effective methods for sterilizing large volumes of this equipment.

Medical isotopes and nuclear medicine are proving to be effective in sterilizing, detecting, and fighting COVID-19 and guiding successful treatment. In addition to damaging the patient’s lungs, this virus also attacks the heart, blood vessels, liver, intestines, brain, and nervous system. It causes blood clots and sometimes strokes or seizures. Unfortunately, as a result, many of our COVID-19 survivors will need serious medical help for months or years to come.

Medical isotopes are being used for lung diagnostics, determining the extent of the patient’s disease, and mapping the COVID-19 proteins, while others are being researched as a possible treatment for combating severe COVID-19 cases. Medical isotopes are necessary for nuclear medicine diagnostic scans to guide the physician in treating our brave survivors.

(more…)

Help May Be On Its Way: 10% Of Worlds Population Suffers From Pain or Depression US Nuclear and Grapheton Develop Neural Technology

Los Angeles, CA.  July 14, 2020 – US Nuclear Corp. (OTC: UCLE), working with a start-up company similar to Elon Musk’s ‘Neuralink’, Grapheton, is eager to announce how Grapheton’s neural stimulation technology can help treat chronic pain and depression.  It is estimated that 500 million people suffer chronic pain worldwide, and 300 million people suffer depression worldwide, affecting more people than any other health burden and adding to suicide and drug addiction rates. These symptoms are mentally and financially devastating to the afflicted persons and their families.  In fact, the total US economic burden of major depressive disorder is now estimated to be $210 billion per year*. Chronic pain and depression are extremely complex disorders that are incredibly hard to treat.  Fortunately, deep brain stimulation is proving to be an effective emerging treatment, and Grapheton has made several significant advances and improvements to the technology to make it even more viable.

Deep brain stimulation involves the surgical implantation of tiny electrodes in your brain that send electrical signals to the areas of your brain where the problems (pain, depression, or movement disorders) originate.  These electrical signals regulate the brain’s activity in that region which can relieve the symptoms.

Depression treatments can range from medications to lifestyle changes, therapy, or any combination of the above.  Unfortunately, some medications just exacerbate the problem, and some people have treatment-resistant depression. Deep brain stimulation is emerging as an effective treatment solution for chronic and resistant depression and has been reported to improve mood, alleviate depression, and lead to an increase in quality of life.

(more…)